ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY BẰNG IMATINIB TẠI BỆNH VIỆN HUYẾT HỌC TRUYỀN MÁU CẦN THƠ
Background: Chronic myeloid leukemia (CML) is a common hematologic malignancy. Previously, treatment mainly focused on controlling leukocytosis and prolonging survival. The advent of targeted therapy has dramatically improved treatment outcomes. Since 2020, when imatinib became covered by health insurance, we have implemented treatment for patients at our hospital.Objective: (1) To describe the clinical and paraclinical characteristics at diagnosis of patients with CML; (2) to evaluate the outcomes of imatinib treatment in CML; (3) to examine the association between EUTOS long-term survival (ELTS) risk groups and the outcomes of imatinib treatment in CML.Subjects and methods: This was a retrospective case series study of CML patients at the Hematology and Blood Transfusion Hospital of Can Tho City from January 2020 to September 2025.Results: The main presenting symptoms were fatigue (64.6%), pallor (57.5%), and splenomegaly (61.4%). The median hemoglobin level was 97 g/L, and the median white blood cell count was 147 G/L. According to the ELTS risk classification, 73.2% of patients were low risk, 18.1% intermediate risk, and 8.7% high risk. Hematologic response rates at 3 and 6 months were 92.9% and 90.1%, respectively. The molecular response rate at 12 months was 87.3% (optimal response 62.0%). The mean overall survival (OS) was 91.7 months, and the mean response survival time was 76.1 months.Conclusion: Treatment of CML with imatinib achieved high response rates and favorable survival.
Authors
- Thien Kim Ly
- Minh Phú Huỳnh
- Văn Thiếu Phạm
- Thị Thu Huyền Lê
- Phương Tuấn Đỗ
- Ngọc Thùy Dương Trương
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0307
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00